Interfering RNA and HIV: Reciprocal Interferences by Corbeau, Pierre
Review
Interfering RNA and HIV: Reciprocal Interferences
Pierre Corbeau*
Laboratoire d’Immunologie, Ho ˆpital Care ´meau, Nı ˆmes and Institut de Ge ´ne ´tique Humaine, CNRS UPR1142, Montpellier, France
Abstract: In this review, a quick presentation of what
interfering RNA (iRNA) are—small RNA able to exert an
inhibition on gene expression at a posttranscriptional
level, based on sequence homology between the iRNA
and the mRNA—will be given. The many faces of the
interrelations between iRNA and viruses, particularly HIV,
will be reviewed. Four kinds of interactions have been
described: i) iRNA of viral origin blocking viral RNA, ii) iRNA
of viral origin downregulating cellular mRNA, iii) iRNA of
cellular origin (microRNA) targeting viral RNA, and iv)
microRNA downregulating cellular mRNA encoding cell
proteins used by the virus for its replication. Next, HIV
strategies to manipulate these interrelations will be
considered: suppression of iRNA biosynthesis by Tat,
trapping by the HIV TAR sequence of a cell component,
TRBP, necessary for iRNA production and action, and
induction by the virus of some microRNA together with
suppression of others. Then, we will discuss the putative
effects of these mutual influences on viral replication as
well as on viral latency, immune response, and viral
cytopathogenicity. Finally, the potential consequences on
the human infection of genetic polymorphisms in
microRNA genes and the therapeutic potential of iRNA
will be presented.
Introduction
The discovery that cells produce small RNAs called interfering
RNAs (iRNAs) that are able to inhibit in a sequence-specific way
gene expression at a post-transcriptional level, a phenomenon
called RNA interference, is a recent breakthrough in biology. This
discovery has already had and will have many consequences on
our knowledge of cell physiology and pathology, on our ability to
regulate protein production at the laboratory, using tailored small
iRNAs (siRNAs), and soon in medicine. Cohabitation of iRNAs
physiologically produced by human cells, called microRNAs
(miRNAs), and viral RNAs in the same cell results in interactions
that may have an impact on virus replication, host cell physiology,
and anti-microbial immune response. In this article, we will
describe briefly the miRNA machinery, review the various
connections existing between iRNAs and HIV RNAs, evaluate
their consequences for both actors, and consider how we could
interfere with these connections in order to regulate virus
infection.
Human Cellular miRNAs
miRNAs are transcribed by intergene regions, introns, and even
exons, either as polycistronic transcripts if they are clustered or as
monocistronic transcripts if they are not [1–3]. These transcripts,
called pri-miRNAs, are imperfect RNA hairpins of hundreds to
thousands of base pairs [4]. They are processed in the nucleus by
the Rnase III endonuclease Drosha to a stem loop structure of
about 60 base pairs, the pre-miRNA (Figure 1) [5]. The transfer of
pre-miRNA from the nucleus to the cytoplasma is mediated by the
nuclear export factor exportin 5 [6]. There, pre-miRNAs are
cleaved by another Rnase III endonuclease, Dicer [7]. Dicer
delivers an approximately 22–base pair duplex. One strand of this
duplex, the mature miRNA, still bound to Dicer, is driven towards
ribosome-free compartments of the cytoplasma called P-bodies
(processing bodies) by an association of molecules called RISC
(RNA-induced silencing complex), which includes the endonucle-
ase Argonaute-2 (Ago-2) [8]. The targets of the miRNA-loaded
RISC are the RNAs presenting with sequence homology with
nucleotides 2–7 in the 59 portion of the miRNA. Most of the time,
the consequence is an inhibition of translation of the mRNA, and
sometimes, particularly if the match between the mRNA and the
miRNA is perfect, the mRNA is cleaved. Of note, TAR RNA–
binding protein (TRBP), a cell protein initially discovered for its
capacity to bind to the TAR sequence of HIV RNA, also binds to
Dicer and Ago-2, and is necessary for the maturation of pre-
miRNA into miRNA as well as for interfering RNA function
[9,10].
A single miRNA targets at least 100 transcripts from various
genes, and one mRNA may be targeted, at its 39 end, by different
miRNAs [11]. Thus, miRNAs, whose number has been estimated to
be340 [12],andmorerecentlyover600 (http://microrna.sanger.ac.
uk/cgi-bin/sequences/mirna_summary.pl?org=hsa), could regu-
late at least one-third of all human genes [13].
Researchers have taken advantage of this pathway to induce the
specific destruction of mRNAs in order to silence genes of choice.
They do so either by directly transfecting siRNAs of approxi-
mately 21 base pairs, or by delivering transgenes encoding hairpin
RNAs, small hairpin RNAs (shRNAs) processed by Dicer to
siRNAs, with a stretch perfectly complementary with the target
mRNA. Now, it happens that some viral RNAs adopt a stem loop
conformation recognized by Drosha or Dicer as a suitable
substrate and are processed to iRNAs, and we will call these viral
iRNAs (viRNAs) to distinguish them from the endogenous cellular
miRNAs. As the characteristics of Drosha and Dicer substrates are
not fully defined, the fact that a viral RNA will or will not be
processed to an iRNA cannot at present be accurately predicted.
Likewise, the characteristics that make an mRNA a target for a
given iRNA, including its own structure [14,15], its accessibility,
i.e., its localization in the cell and its association with other
components of the cell [16], are not absolutely established.
Consequently, any bioinformatic study predicting that a viral
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silenced by an iRNA has to be confirmed experimentally. It must
also be kept in mind that many studies analyze the effect on viral
RNA of iRNAs at high concentrations obtained after transfection,
and that such results must be confirmed in the course of the
infection at physiological concentrations of iRNAs.
RNA Interferences in the Cell/Virus Complex
Viral RNAs and the miRNA machinery may interfere in
various ways (Figure 2). First, the viRNAs generated by the cell
from virus RNAs may target back viral RNAs (pathway 1), but also
cell mRNAs that happen to share some sequence homology with
them (pathway 2). Second, cellular miRNAs may recognize viral
RNAs and silence them (pathway 3). Finally, the cell may produce
miRNAs that control the expression of a cellular protein necessary
for the virus life cycle (pathway 4). We will review these various
possibilities, comparing examples of what is already known for
other viruses with what is known for HIV.
Autosilencing: viRNA against viral RNA (pathway
1). Obviously, some viRNAs will match exactly with some
viral RNAs issued from the same genomic sequence, and induce
their destruction. This is the case, for instance, in the course of
simian virus 40 (SV40) infection. The virus encodes two RNAs
with a stem loop structure that are transformed by the host cell
into miR-S1s that are complementary to mRNA coding for the
viral T antigen. Consequently, T antigen mRNA is degraded [17].
In this scenario, host miRNA machinery turns viral RNA against
viral RNA. The same phenomenon has been looked for in HIV
infection. A precursor [18] and a recent [19] study by two major
groups in the field failed to identify iRNA of HIV origin in infected
cells. Yet, a nef- and LTR-specific HIV miRNA able to inhibit
LTR-driven transcription has been evidenced by another group
[20,21]. Moreover, a fourth group has reported that a stem loop
HIV RNA can be processed by Dicer to a viRNA able to target
env mRNA and that transfection of the corresponding shRNA
inhibited over 80% of env mRNA production [22], a result that
was challenged later [19]. Finally, Klase et al. [23] and Ouellet et
al. [24] have shown that TAR is a source of viRNAs: Dicer
interacts with TAR, and cleaves it to produce TAR-derived
viRNAs able to exert gene downregulatory effects. The level of
anti-HIV activity of this pathway, which is controversial, remains
to be evaluated in the context of the infection. Anyway, the
antiviral effect of HIV viRNAs is at best partial.
viRNA against cell mRNA (pathway 2). It may happen that
the host cell transforms a viral RNA into a viRNA with some
degree of homology with a cell mRNA. In this case, the viRNA
will inhibit the expression of the corresponding cellular gene. Such
a possibility has been recently described during human
cytomegalovirus (HCMV) infection. HCMV encodes an RNA
transformed by the infected cell into a viRNA, hcmv-miR-UL112,
that blocks the translation of major histocompatibility complex
class I–related chain B (MICB). Of note, MICB is a stress-induced
molecule expressed on HCMV-infected cells that is recognized by
the natural killer (NK) cell activating receptor NKG2D [25].
Likewise, are there viRNAs of HIV origin able to target cell
mRNAs? Computer-directed analyses have evidenced regions of
base complementarity between HIV-1 sequences and human
Figure 1. Biosynthesis and Activity of iRNAs
doi:10.1371/journal.ppat.1000162.g001
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IL-3, IL-12, and TNFb [26]. Moreover, Bennasser et al. have
predicted the existence of five HIV RNAs that could be
transformed by Dicer into five viRNAs able to target various
cellular mRNAs [27]. If these predictions are experimentally
confirmed, HIV could also manipulate cellular biology and host
immune response via viRNAs that were produced by the infected
cell.
Cellular miRNA against virus RNA (pathway
3). Sometimes the cell does not borrow viral RNAs to produce
viRNAs with antiviral activity, but rather uses its own miRNAs. A
striking example of this strategy is represented by the cell miR-32
that targets the open reading frame 2 of the primate foamy virus
type 1, thereby inhibiting virus translation [28]. In this way, a
cellular miRNA may directly target a virus RNA and block virus
production. Interestingly, the same process results in the opposite
effect for hepatits C virus (HCV). The endogenous miR-122,
which is specifically produced by liver cells, binds to the 59
noncoding region of HCV, but, unusually, this results in an
increase in viral RNA replication through a mechanism that
remains to be unraveled [29]. Interactions between cellular
miRNAs and HIV RNAs may also exist, in so far as an in silico
study predicted that five human miRNAs, expressed in T cells,
might target nef, vpr, vif, and env RNAs [30]. Recently, Huang et
al. have shown that miR-28, -125b, -150, -223, and -382, cellular
miRNAs that are overexpressed in quiescent T4 lymphocytes,
target sequences in the 39 end of HIV-1 RNA, silencing thus
almost all viral messengers [31]. Neutralizing these cellular
miRNAs by transfecting specific antagonists into nonactivated
T4 cells from patients with HIV under highly active antiretroviral
therapy increased by 10-fold the in vitro efficiency of virus
isolation. These observations strongly argue for a role of cellular
miRNAs in HIV latency. This hypothesis, together with the
suppression exerted by HIV on miRNA biosynthesis, might partly
explain why HIV has not mutated to escape from the inhibitory
effect of iRNAs of viral or cellular origin.
Cellular miRNA targeting cell mRNA encoding proteins
involved in virus replication (pathway 4). Finally, a fourth
situation, where host miRNAs limit viral proliferation by acting on
cellular mRNA, has been recently proposed for HIV [32].
Triboulet et al. have shown that the cellular miRNAs miR-17-
5p and miR-20 silence the mRNA encoding the histone acetylase
PCAF. PCAF has been previously presented as a host cofactor for
Tat transactivation of HIV LTR, and as being recruited by Tat
and remodeling the histone architecture in the vicinity of the LTR,
promoting thereby HIV gene expression (Figure 3A). This is to say
that human cells seem to permanently downregulate HIV-1
replication by depriving the infected cell of an endogenous enzyme
that could be necessary for virus gene expression.
Regulation of the miRNA Pathway by the Virus
The few examples we have just reviewed suggest that, most of
the time, the miRNA machinery works against the virus. It is not
surprising then, that many viruses have elaborated strategies to
subvert this machinery. And HIV is not the last one.
Inhibition of miRNA production: viral suppressors of
RNA silencing. A strategy adopted by many viruses involves
binding to a component of the miRNA machinery in order to
Figure 2. Interactions between iRNAs, Cellular mRNAs, and HIV RNAs
doi:10.1371/journal.ppat.1000162.g002
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nucleo-cytoplasmic transport of pre-miRNA by forming a complex
with exportin 5 [33]. HIV seems to target two other factors of
RNA silencing, Dicer and TRBP (Figure 4). Bennasser et al. have
shown that purified Tat protein inhibits the capacity of Dicer to
process double-stranded RNA to short iRNAs in vitro [22].
Moreover, the TAR and RRE sequences of HIV RNA, by
recruiting TRBP, could competitively inhibit the effect of TRBP
on pre-miRNA processing and on miRNA function [34,35]. Yet,
the capacity of Tat to hinder miRNA biogenesis has been recently
challenged [19], and the impact on HIV infection of these
inhibitions of miRNA expression remains to be quantified.
Anyhow, if HIV encodes suppressors of RNA silencing, their
effect is obviously incomplete.
This double mechanism of suppression of RNA silencing
strongly suggests that the interest of HIV is to counteract RNA
interference; that is to say, the effect of the miRNA machinery is
globally harmful for the virus. In support of this notion, a point
mutation in Tat, which abrogates its inhibitory effect on Dicer, but
not its transactivation effect on HIV LTR, results in a reduction in
virus replication [22]. Likewise, Haasnoot et al. have shown that a
Tat protein able to block Dicer activity is necessary for efficient
HIV production [36]. Moreover, Triboulet et al. have reported
that the inhibition of Drosha or Dicer using specific siRNA
increases HIV replication in peripheral blood mononuclear cells
from individuals with HIV [32].
Viral up- and downregulation of miRNA
concentrations. In addition to globally diminishing miRNA
production, viruses may also specifically regulate, positively or
negatively, the level of expression of some miRNAs. This is the
case for tobacco mosaic virus, where infection results in an
increase in miR-156, -160, -164, -166, -169, and -171 in Nicotiana
tabacum [37]. HIV infection also results in such a phenomenon.
Triboulet et al. have reported that the infection of a lymphoid
cell line by HIV-1 downregulates six miRNAs, including miR-
17-5p and miR-20, and upregulates eleven others, including
miR-122, -297, -370, and -373 [32]. The mechanism responsible
for this selective regulation by HIV remains to be unveiled.
During tobacco mosaic virus infection, it is the accumulation of
two viral proteins, the movement protein and the coat protein,
that is responsible for the change in miRNAs concentrations
[37]. Of note, two of the miRNAs downregulated during HIV
infection are precisely miR-17-5p and miR-20, which target the
Tat cofactor PCAF. Thus, by reducing the amount of miR-17-5p
and miR-20 available, the virus alleviates the negative control
Figure 3. Inhibition of HIV Expression by the Silencing Exerted by miR-17-5p and miR-20 on PCAF (A), and Downregulation of This
Inhibition by HIV (B)
doi:10.1371/journal.ppat.1000162.g003
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transcription (Figure 3B).
Consequences of the Interactions between iRNAs
and the Other RNAs during Infection
Thus, viruses and the miRNA machinery of the host cell
interact in various ways. These interactions may have conse-
quences on the replication and the pathogenicity of the virus, but
also on the immune response of the host.
Consequences for virus replication/latency. Interactions
between iRNAs and other RNAs in the infected cell may have
consequences on the virus life cycle, mostly negative, with one
exception, HCV. For HIV, viRNA complementary to env, nef,
and/or LTR sequences [20–22] and cellular miRNAs targeting
the 39 end of HIV RNAs [31] could inhibit virus replication.
Moreover, the cellular miR-17-5p and miR-20, through their
repression of PCAF expression (Figure 3B), seem to exert the same
effect [32]. In these various ways, RNA interference might
downregulate HIV production. Logically, the virus tries to counter
this effect by blocking Dicer activity and by hijacking TRBP.
The global impact on in vivo infection of the interplay between
virus and cell RNAs, and the relative importance of each
interaction, remain to be determined. This interplay could
influence the efficiency of HIV replication, and thereby the rate
of disease progression, but it could also be involved in HIV latency
and in the constitution of the viral reservoir. Finally, differences in
the anti-HIV efficiency of RNA inteference could exist between
individuals. These differences might be due to genetic polymor-
phisms in sequences regulating miRNA gene transcription or
stability, as well as polymorphisms in cellular miRNA sequences
resulting in variations in processing or targeting as already
described for miR-138-2 and miR-30c-2 [38].
Consequences on the immune response. Inhibition of
virus gene expression by RNA interference may downregulate
virus replication in vitro, but in vivo, this downregulation might
help the virus to escape from the immune response. This is the
case for the above-mentioned inhibition exerted by the SV40
miRNAs miR-S1s on the T antigen (see ‘‘Autosilencing: viRNA
against virus RNA (pathway 1)’’). This inhibition occurs late
enough in the virus life cycle not to hinder SV40 replication, but
early enough to reduce T lymphocyte cytotoxicity and interferon-c
production triggered by the presence of the viral T antigen [17].
The targeting of cell mRNA by viRNA (pathway 2) may also result
in the reduction of immune response. This possibility is illustrated
by the inhibition of MICB, a ligand for NK cell activating
receptor, by an HCMV miRNA (‘‘viRNA against cell mRNA
(pathway 2)’’). This targeting is not innocent, since it results in a
decrease in antiviral NK activity. Some cellular miRNAs are
involved in innate immunity, e.g., miR-155 induced by Toll-like
receptor ligands or interferon-b (IFN-b) [39] and miRNA let-7a
mediating IL-6-induced cell survival [40]. Some cellular miRNAs
are involved in specific immunity, e.g., miR-155 regulating genes
driving functions of lymphocytes [41,42], miR-150 controlling the
differenciation of B cells via c-Myb [43], and miR-181a
modulating the antigen sensitivity of T cells [44]. A striking
Figure 4. Regulation of the miRNA Machinery by HIV
doi:10.1371/journal.ppat.1000162.g004
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lately given by Pedersen et al. This group has reported that some
of the anti-HCV effect of IFN-b is mediated by five cellular
miRNAs, induced by IFN-b, that target HCV RNA [45].
Consequently, changes in miRNA expression induced by HIV
might also alter the immune response.
Consequences on the pathogenicity. These virus/cell,
iRNA/RNA interactions could also have consequences on the
pathogenicity of the infection. Because cellular miRNAs regulate
major mechanisms of cell physiology, such as proliferation,
differentiation, apoptosis, or tumorogenicity [46], targeting of
cell mRNAs by viRNAs (pathway 2) and/or specific or global
virus-induced disturbance of the cellular miRNA production
might have pathogenic effects. The extent to which the
modifications of host biology observed in individuals with HIV
are mediated by RNA interference remains to be addressed,
however.
Therapeutic Opportunities
Besides strategies using synthetic interfering RNAs (siRNAs or
shRNAs) to target mRNA encoding cell proteins necessary for
virus replication or directly target HIV RNA, the knowledge of
HIV RNA/RNA silencing connections might pave the way for
new therapeutic approaches. The fact that siRNAs or siRNAs
antagonists modified chemically for stability and conjugated to
cholesterol or liposomes have a specific, long-lasting, and
ubiquitous effect when administrated intravenously [47,48] is
particularly encouraging for this kind of approach.
As interfering RNAs disturb HIV replication, the possibility to
act on the viral infection through miRNAs must be considered. At
least two opposite strategies may be proposed. First, the miRNA
machinery could be manipulated in order to hinder virus
replication. Second, because of the involvement of miRNA in
HIV latency, the miRNA machinery could be manipulated in
order to provoke virus replication in the reservoir cells with the
aim of lysing them. This second approach has the advantage of
only requiring a brief treatment that is sufficient to induce HIV
expression in infected, non-productive quiescent cells. To reach
this goal, a possibility is to target host miRNA. For instance, the
neutralization of miR-17 and miR-20 by specific inhibitors should
release the inhibition exerted by these miRNAs on PCAF and
hopefully trigger HIV replication in reservoir cells, resulting in the
eradication of this population. A drawback of such a strategy is
that the inhibition of a given miRNA will increase the level of
expression of all of its mRNA targets with possible side effects. As
our knowledge on the impact of the disturbance induced by HIV
on host immunity and cell physiology increases, new therapeutic
strategies may arise.
Last, the manipulation of miRNAs in order to boost HIV
production in vitro may ameliorate the efficiency of virus recovery
from patients’ cells [31,32], and of virus mass production.
Conclusion
The miRNA pathway appears to be a new branch of natural
antiviral immunity. Understanding the complex relationship that
exists between the miRNA pathway and HIV will enlighten the
physiopathology of the infection and offer new therapeutic
strategies. As miRNA might be involved in HIV replication and
latency, pathogenicity, and immune response, manipulating
miRNA might enable us to modulate all of these aspects of the
infection. Much remains to be discovered with surprises on the
way. For instance, the eventuality that miRNA might also regulate
DNA transcription in mammal cells [49] by inducing DNA
methylation [50] and/or other mechanisms [51,52] could offer
additional means to inhibit HIV replication, as suggested by recent
data [23,53].
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